Jagsonpal Pharmaceuticals reported its Q1FY26 results showing a 23.1% revenue increase to Rs. 756 Mn, EBITDA at Rs. 157 Mn with a margin of 20.8%, and PAT doubled to Rs. 108 Mn on July 26, 2025.
AI Assistant
Jagsonpal Pharmaceuticals Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.